一名成年人在接种国药集团北京生物新冠疫苗（BBIBP-CorV）后发生硬化性黏液水肿：一种极其罕见的现象。
Scleromyxedema in an adult following Sinopharm BBIBP-CorV vaccination: An extremely rare phenomenon.
作者信息
Parsaei Amirhossein, Rezaei Somayeh Sadat, Rahmani Alireza, Masoumi Maryam, Dehghanbanadaki Hojat, Norouzi Somayyeh, Riyahi Mohammad Mehdi, Tabaraii Reihane, Montazeri Seyed Mohammad Hashem
机构信息
Faculty of Medicine, Tehran University of Medical Science, Tehran, Iran.
Department of Rheumatology, Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
出版信息
J Scleroderma Relat Disord. 2023 Jun;8(2):NP9-NP12. doi: 10.1177/23971983221107321. Epub 2022 Jun 30.
INTRODUCTION
The Sinopharm BBIBP-CorV vaccine produces a variety of cutaneous adverse effects. Scleromyxedema is a mucinous connective tissue disorder that causes skin thickness and sclerodermoid changes. According to our findings, this is the first case of scleromyxedema induced by the Sinopharm immunization.
CASE DESCRIPTION
We discuss the case of a 75-year-old woman who acquired progressive thickening of the skin in her limbs and trunk after getting the Sinopharm vaccination. Examination, laboratory testing, and a biopsy were used to verify scleromyxedema diagnosis. Intravenous immunoglobulins, mycophenolate mofetil, and prednisolone were used in the treatment of the patient. The outcomes from the 4-month follow-up were reassuring.
CONCLUSION
This study emphasizes the need of considering scleromyxedema as a connective tissue pathology in patients who have recently received Sinopharm vaccine and have similar cutaneous signs.
引言
国药集团北京生物制品研究所有限责任公司的新冠病毒灭活疫苗（BBIBP-CorV）会产生多种皮肤不良反应。硬化性黏液水肿是一种黏液性结缔组织疾病，可导致皮肤增厚和硬皮样改变。根据我们的研究结果，这是首例由国药集团疫苗接种引起的硬化性黏液水肿病例。
病例描述
我们讨论了一名75岁女性的病例，她在接种国药集团疫苗后，四肢和躯干皮肤逐渐增厚。通过检查、实验室检测和活检来确诊硬化性黏液水肿。患者接受了静脉注射免疫球蛋白、霉酚酸酯和泼尼松龙治疗。4个月随访结果令人放心。
结论
本研究强调，对于近期接种过国药集团疫苗且有类似皮肤症状的患者，需要考虑将硬化性黏液水肿作为一种结缔组织病理情况。
Zotero 插件